Company
Eucalyptus Health
Telehealth group founded in Sydney in 2019, operating four direct-to-consumer clinical brands: Juniper (weight management built around GLP-1 receptor agonist prescribing plus coaching), Pilot (men's health, including weight, hair loss and sexual health), Software (dermatology and skincare) and Kin (contraception, fertility and pregnancy). Its longevity relevance is distribution rather than discovery: it does not develop drugs or run biology research, but is one of the larger channels in Australia through which GLP-1 metabolic therapy is prescribed, titrated and monitored remotely, with adherence support attached. Reported 2024 revenue of A$120.9m and an after-tax loss of A$15.2m. Qualifies under limb (b), Australia-headquartered, though since June 2026 it has been a wholly owned subsidiary of NYSE-listed Hims & Hers Health rather than an independent company.
At a glance
- Listing
- No listing on file
- Category
- GLP-1 and metabolic
- Headquarters
- Sydney, New South Wales, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- GLP-1 and metabolic
- Market
- Australia
- Recent inflection
- Hims & Hers Health (NYSE: HIMS) completed its acquisition of Eucalyptus on 2 June 2026, for aggregate consideration of up to US$1.15bn subject to adjustments, per the acquirer's press release filed as an 8-K exhibit with the SEC. The deal was announced in February 2026; founder Tim Doyle moved into an international operations role at the acquirer.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Acquired |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Sydney, New South Wales, Australia
- Website
- en.wikipedia.org
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Hims & Hers Health (NYSE: HIMS) completed its acquisition of Eucalyptus on 2 June 2026, for aggregate consideration of up to US$1.15bn subject to adjustments, per the acquirer's press release filed as an 8-K exhibit with the SEC. The deal was announced in February 2026; founder Tim Doyle moved into an international operations role at the acquirer.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Eucalyptus Health · Wikipedia
- Hims & Hers Completes Acquisition of Eucalyptus (Form 8-K exhibit 99.1) · U.S. Securities and Exchange Commission / Hims & Hers Health, Inc.
- Hims & Hers Completes Acquisition of Eucalyptus · Hims & Hers Health, Inc. investor relations
Every entity profile on variis is sourced. Not investment advice.